Oscient’s Factive To Get Advisory Committee Review For Acute Bacterial Sinusitis
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Anti-Infective Drugs Advisory Committee will review Oscient’s sNDA for the antibiotic Sept. 12.
You may also be interested in...
BrainStorm’s ALS Treatment NurOwn, Filed Over Protest, Will Get US FDA Panel Review
A November 2022 refuse-to-file letter cited clinical and statistical issues for the stem cell therapy, which failed its Phase III clinical efficacy endpoint. However, BrainStorm has consistently asserted that NurOwn demonstrated benefit in patients with less advanced disease at baseline, and it is encouraged by regulatory flexibility FDA recently has shown for the neurodegenerative disease.
Schering’s Antibiotic Garenoxacin Gets Advisory Committee Date
FDA's Anti-Infective Drugs Advisory Committee will discuss Schering-Plough's antibiotic garenoxacin on Sept. 11, according to a Federal Register pre-publication announcement July 24
Schering’s Antibiotic Garenoxacin Gets Advisory Committee Date
FDA's Anti-Infective Drugs Advisory Committee will discuss Schering-Plough's antibiotic garenoxacin on Sept. 11, according to a Federal Register pre-publication announcement July 24